Rapid expansion of global vaccine campaign against pneumonia 'unprecedented'

NewsGuard 100/100 Score

"A global push to bring a vaccine against the bacterial cause of pneumonia to communities that need it most is ramping up quickly, expanding to nearly 60 countries in the next five years," PBS NewsHour's "The Rundown" reports. "At least three million child deaths could be prevented in the next decade through the global vaccine rollout, according to a new analysis published Thursday in the journal of the Royal Society of Tropical Medicine and Hygiene by health experts from Children's Hospital Boston and Johns Hopkins University, among others," the blog states, adding, "More new research released this week by Johns Hopkins Bloomberg School of Public Health called the rate of the rollout and its quick expansion 'unprecedented.'"

The blog includes a video preview of Friday's NewsHour, in which "Ray Suarez reports from Nicaragua, the first country to receive the vaccine as part of the new campaign, and examines the market corporate-government-NGO agreement that made it possible for poor countries to afford it" (11/10).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Nigeria first to rollout new Men5CV vaccine against meningitis